A Comparative Study of 5-ethyl-2′-Deoxyuridine and Selected Lipophilic 5,6-Dihydro Double/Triple Prodrugs

(+)-Trans-(5R,6R)-5-bromo-5-ethyl-6-ethoxy-5,6-dihydro-5′-O-valeryl-2′-deoxyuridine (3) and (+)-trans-(5R,6R)-5-bromo-5-ethyl-6-ethoxy-5,6-dihydro-3′,5′-di-O-valery[-2′-deoxyuridine (4) were synthesized in 55% and 8.6% yield, respectively, by esterification of the 5′-hydroxyl group of (+)-trans-(5R,6R)-5-bromo-5-ethyl-6-ethoxy-5,6-dihydro-2′-deoxyuridine (2) using valeryl chloride. [4-14C]-3 and [4-14C]-4 were synthesized in 79% and 64% chemical and radiochemical yield, respectively, by similar esterifications of [4-14C]-2. The double prodrug 3 was readily hydrolysed (> 95% in 8 min) to 5-ethyl-2′-deoxyuridine (EDU) by porcine liver esterase in vitro. The biotransformations of 2 and 3 were studied following i.v. injection of a 0.4 mmol/kg i.v. dose to male Balb/c mice. The single prodrug 2 was rapidly cleared (<10 min) from the blood. The area under the blood concentration-time curve (AUC) for EDU, as a metabolite of 2, was higher (2.1 ± 0.4 μmol.h.g−1) than the AUC observed when EDU itself was injected (1.7 ± 0.2 μmol.h.g−1). The double prodrug 3 provided a sustained high concentration of EDU in blood, with an AUC for EDU, as a metabolite of 3, of 1.8 ± 0.2 μmol.hr.g−1. 5′-O-Valeryl-5-ethyl-2′-deoxyuridine and 3 were both detected in blood samples collected up to 35 min post i.v. injection. 5-Ethyluracil and 5-(1-hydroxyethyl)-uracil were identified as secondary metabolites of EDU, 2 and 3. Compared to [4-14C]-EDU, i.v. injection of [4-14C]-3 or [4-14C]-4 provided significantly higher (P < 0.001) radioactivity levels in the brain, but neither EDU, 2 or 3 protected mice against intracerebral herpes simplex virus infection. Hepatic uptakes of 2, 3 and 4, in mice, were similar to each other despite the respective substantial increases in both molecular weight and lipophilicity of this series. In rats, biliary excretion over the 0-4 h period after i.v. injection accounted for only 2.9-3.9% of the injected dose for these prodrugs.

[1]  L. Wiebe,et al.  Synthesis and biodistribution of [4-14C]-5-bromo-6-methoxy-5,6-dihydro-prodrug derivatives of 5-ethyl-2'-deoxyuridine. , 1994, Drug design and discovery.

[2]  L. Wiebe,et al.  Synthesis, biotransformation, pharmacokinetics, and antiviral properties of 5-ethyl-5-halo-6-methoxy-5,6-dihydro-2'-deoxyuridine diastereomers. , 1994, Biochemical pharmacology.

[3]  S. Wallace,et al.  HERPES SIMPLEX VIRUS ENCEPHALITIS: PROBLEMS IN DIAGNOSIS , 1992, Developmental medicine and child neurology.

[4]  B. Sköldenberg Herpes simplex encephalitis. , 1991, Scandinavian journal of infectious diseases. Supplementum.

[5]  E. De Clercq,et al.  Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo , 1989, Antimicrobial Agents and Chemotherapy.

[6]  H. Bundgaard The double prodrug concept and its applications , 1989 .

[7]  E. Clercq,et al.  Mechanism of Antiviral Activity of 5-Ethyl-2′-Deoxyuridine , 1987 .

[8]  L. Wiebe,et al.  An improved synthesis of 14C-labelled 2,2'-anhydrouridine, 2'-deoxyuridine and 5-ethyl-2'-deoxyuridine , 1986 .

[9]  E. De Clercq,et al.  Prodrugs of 5‐Ethyl‐2′‐deoxyuridine, II Syntheses and Antiviral Activities of 5′‐ and 3′‐Ester Derivatives , 1986, Archiv der Pharmazie.

[10]  E. De Clercq,et al.  Selective in vitro and in vivo activities of 5-(2-haloalkyl)pyrimidine nucleoside analogs, particularly 5-(2-chloroethyl)-2'-deoxyuridine, against herpes simplex virus , 1985, Antimicrobial Agents and Chemotherapy.

[11]  S. Sacks,et al.  Susceptibility of recent clinical isolates of herpes simplex virus to 5-ethyl-2'-deoxyuridine: preferential inhibition of herpes simplex virus type 2 , 1983, Antimicrobial Agents and Chemotherapy.

[12]  Victor A. Levin,et al.  RELATIONSHIP OF OCTANOL/WATER PARTITION COEFFICIENT AND MOLECULAR WEIGHT TO RAT BRAIN CAPILLARY PERMEABILITY , 1980 .

[13]  J. Taylor,et al.  5-Ethyl-2'-deoxyuridine as a systemic agent for treatment of herpes simplex virus encephalitis. Comparison of effects in a normal and immunosuppressed murine model. , 1979, Advances in ophthalmology = Fortschritte der Augenheilkunde = Progres en ophtalmologie.

[14]  L. Wiebe,et al.  Excretion patterns of 125I-radioiodohippuric acid in normal and in chronically uremic rats. , 1978, International journal of nuclear medicine and biology.

[15]  E. De Clercq,et al.  Antiviral activity of 5-ethyl pyrimidine deoxynucleosides. , 1975, Biochemical pharmacology.

[16]  D. Shugar,et al.  A nonmutagenic thymidine analog with antiviral activity. 5-Ethyldeoxyuridine. , 1969, Journal of medicinal chemistry.

[17]  J. Burchenal,et al.  Nucleosides. XXXVII. 5,6-substituted 5-fluorodihydropyrimidines and their 2'-deoxyribonucleosides. , 1967, Journal of medicinal chemistry.